Prevalence of topoisomerase I genetic mutations and UGT1A1 olymorphisms associated with irinotecan in individuals of Asian descent

Oncology Letters

Volumn 2, Issue 5, 2011, Pages 923-928

  Fukui, Tomoya ^a   Mitsufuji, Hisashi ^a   Kubota, Masaru ^a   Inaoka, Hidenori ^a   Hirose, Minoru ^a   Iwabuchi, Keiichi ^a   Masuda, Noriyuki ^a   Kobayashi, Hirosuke ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

CPT 11; Mutation; Polymorphism; Topoisomerase I; UGT1A1

Indexed keywords

DNA TOPOISOMERASE; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN;

AFRICAN AMERICAN; ARTICLE; CANCER TISSUE; CAUCASIAN; CLINICAL ARTICLE; DNA SEQUENCE; EXON; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; JAPANESE; LUNG ADENOCARCINOMA; LUNG CARCINOMA; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79960320017     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.346     Document Type: Article

References (24)

1. Pizzolato JF and Saltz LB: The camptothecins. Lancet 361: 2235-2242, 2003.
2. Arakawa Y, Suzuki H, Saito S and Yamada H: Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells. Mol Cancer Ther 5: 502-508, 2006.
3. Kubota N, Kanzawa F, Nishio K, Takeda Y, Ohmori T, Fujiwara Y, Terashima Y and Saijo N: Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem Biophys Res Commun 188: 571-577, 1992.
4. Chang JY, Liu JF, Juang SH, Liu TW and Chen LT: Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res 62: 3716-3721, 2002.
5. Chrencik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, Stewart L and Redinbo MR: Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol 339: 773-784, 2004.
6. Redinbo MR, Stewart L, Kuhn P, Champoux JJ and Hol WGJ: Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279: 1504-1513, 1998.
7. Laco GS, Collins JR, Luke BT, Kroth H, Sayer JM, Jerina DM and Pommier Y: Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model. Biochemistry 41: 1428-1435, 2002.
8. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G and Sparreboom A: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7: 2182-2194, 2001.
9. Humerickhouse R, Lohrbach K, Li L, Bosron WF and Dolan ME: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60: 1189-1192, 2000.
10. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191, 1991.
11. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K and Hasegawa Y: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60: 6921-6926, 2000.
12. Ando Y, Fujita K, Sasaki Y and Hasegawa Y: UGT1A1*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Curr Opin Mol Ther 9: 258-262, 2007.
13. Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, Miya T, Kodama K, Narabayashi M and Sasaki Y: Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97: 1255-1259, 2006.
14. Strassburg CP: Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics. 9: 703-715, 2008.
15. Saito A, Kawamoto M and Kamatani N: Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects. J Hum Gen 54: 317-323, 2009.
16. Kaniwa N, Kurose K, Jinno H, Tanaka-Kagawa T, Saito Y, Saeki M, Sawada K, Tohkin M and Hasegawa R: Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab Dispos 33: 458-465, 2005.
17. Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, Paré L, Culverhouse R, McLeod HL and Baiqet M: Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 14: 1788-1796, 2008.
18. Chowbay B, Zhou S and Lee EJ: An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev 37: 327-378, 2005.
19. Mercke Odeberg J, Andrade J, Holmberg K, Hoglund P, Malmqvist U and Odeberg J: UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females. Eur J Clin Pharmacol 62: 829-837, 2006.
20. Liu JY, Qu K, Sferruzza AD and Bender RA: Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals. Anticancer Drugs 18: 693-696, 2007.
21. Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H, Ratain MJ and Di Rienzo A: Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12: 725-733, 2002.
22. Tsurutani J, Nitta T, Hirashima T, Komiya T, Uejima H, Tada H, Syunichi N, Tohda A, Fukuoka M and Nakagawa K: Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. Lung Cancer 35: 299-304, 2002.
23. Moisan F, Longy M, Robert J and Le Morva V: Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines. Br J Cancer 95: 906-913, 2006.
24. Saito Y, Maekawa K, Ozawa S and Sawada J. Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in east Asians and their comparison with other ethnic populations. Curr Pharmacogenomics 5: 49-78, 2007.